Literature DB >> 12070442

Case presentation of gastrinoma combined with gastric carcinoid with the longest survival record -- Zollinger-Ellison syndrome: pathophysiology, diagnosis and therapy.

Stanisław J Konturek1, Piotr C Konturek, Władysław Bielański, Krzysztof Lorens, Edward Sito, Jan W Konturek, Sławomir Kwiecień, Andrzej Bobrzyński, Teresa Pawlik, Danuta Karcz, Hany Areny, Tomasz Stachura.   

Abstract

BACKGROUND: Zollinger-Ellison syndrome is a very rare disease caused by tumor with gastrin producing cells accompanied by hypergastrinemia leading to gastric hypersecretion and peptic ulcers and their complications. CASE STUDY: Female case of gastrinoma (Zollinger-Ellison syndrome; Z-E) with a record of 38 yrs of survival. Acute gastro-duodenal ulcers started at 28 yr of age and Z-E was diagnosed by using gastrin assays. Basal and maximal acid outputs and ratio of basal/maximal outputs were away over normal limits. Because of ulcer recurrence and complications, patient was subjected to several gastric surgeries but refused total gastrectomy. She was also treated with many H2-receptor (R) antagonists and proton-pump inhibitors (PPI), each new drug being initially highly effective but then showing declining efficacy except when PPI, lansoprazole was used. The gastrin level rose in the course of disease from initial high value of 2000 pg/mL to the extreme 4500 ng/mL at present. During the last 2 yrs, metastasis mainly to liver developed and they were successfully treated by synthetic octapeptide derivative of somatostatin and, as a result, metastatis partly reduced and plasma gastrin drasticly decreased. Biopsy taken from liver metastasis showed the presence of typical gastrinoma cells with gastrin and chromogranin, while that from oxyntic mucosa revealed the ECL-cell hyperplasia with carcinoid tumors and unexpected gastric atrophy.
CONCLUSIONS: This phenomenal case described in this article might be the new proven evidence needed by gastroenterologists to overturn the traditional treatment using total gastrectomy as a treatment of choice to the partial gastrectomy combined with proton pump inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070442

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  3 in total

1.  Biomarkers in various types of atrophic gastritis and their diagnostic usefulness.

Authors:  Kazimierz Rembiasz; Peter C Konturek; Danuta Karcz; Stanislaw J Konturek; Władysław Ochmanski; Wladyslaw Bielanski; Andrzej Budzynski; Jerzy Stachura
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

2.  Gastric carcinomas localized to the cardia.

Authors:  Karin E Bakkelund; Ivar S Nordrum; Reidar Fossmark; Helge L Waldum
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

Review 3.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.